Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma

Disease Area: Brain Cancer
Investigator: Christine Brown
Institution: City of Hope, Beckman Research Institute
CIRM Grant: CLIN2-10248
Award Value: $12,753,854
Trial Sponsor: Beckman Research Institute of City of Hope
Trial Stage: Phase 1
Trial Status: Recruiting
Targeted Enrollment: 92
ClinicalTrials.gov ID: NCT02208362

Details:
A team at the City of Hope led by Dr. Christine Brown is pursuing a Phase 1 trial targeting an aggressive brain cancer called malignant glioma. City of Hope will re-engineer a patient’s immune system central memory T cells (TCM cells) to express chimeric antigen receptors (CAR). These CAR-T cells will recognize a molecular marker on the surface of glioma cancer stem cells and kill the tumors. Dr. Brown’s award to pursue CAR-T therapy for solid cancers comes at an exciting and opportune time with the recent U.S. Food and Drug Administration (FDA) approval of the first CAR-T therapy, called Kymriah, for patients with acute lymphoblastic leukemia, a deadly form of blood cancer.

Design:
Non-randomized, open-label treatment.

Goal:
Determine safety, feasibility, and efficacy.

News about this clinical trial:
City of Hope Scientist Christine Brown Receives $12.8M Grant from CIRM to Fund Trial for Brain Cancer

Source URL: https://www.cirm.ca.gov/clinical-trial/phase-i-study-chimeric-antigen-receptor-engineered-central-memory-t-cells-treatment-0